Enterprise Value

462.4M

Cash

441M

Avg Qtr Burn

-79.48M

Short % of Float

22.84%

Insider Ownership

0.73%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
THIOLA® EC (tiopronin) Details
Kidney disease, Cystinosis

Approved

Quarterly sales

FILSPARI (Sparsentan) Details
Kidney disease, IgA nephropathy

Approved

Quarterly sales

FILSPARI (Sparsentan) Details
Kidney disease, IgA nephropathy

PDUFA

Approval decision

Phase 3

Data readout

Phase 3

Data readout

Sparsentan Details
Kidney disease, Focal segmental glomerulosclerosis

Phase 3

Update

Sparsentan Details
Kidney disease, Glomerular diseases

Phase 2

Update